9 news items
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include
hfjoexzedw5dy1jbhh03qeot5knz5emlg0b0csi3xao
TAK
18 Apr 24
not expect a material impact on the consolidated financial statements as a result of this approval
7vuh4oejakw0wtq0u49aq2gggjxv6ujglsrf12azq8
TAK
26 Mar 24
presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda
grx806rhheuvdhwd1f37qz jzk4pnoi98jug8y7cfatl1858m5hnkc
TAK
13 Mar 24
-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release
j5gn7ua7a g3o2f
TAK
26 Feb 24
and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release
- Prev
- 1
- Next